Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer

Phase 2

Completed

Conditions: Stomach Neoplasms
Neoplasms Metastasis
ERBB2 Gene Amplification

Interventions: Drug: Trastuzumab
Drug: Docetaxel
Drug: Capecitabine

First Posted Date: 2013-12-09

Last Posted Date: 2016-11-18

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 67

Registration Number: NCT02004769

Locations: 🇨🇳
Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer

Conditions: Metastatic Gastric Cancer

Interventions: Drug: FOLFOX
Drug: Capecitabine

First Posted Date: 2013-12-05

Last Posted Date: 2019-02-27

Lead Sponsor: International Group of Endovascular Oncology

Target Recruit Count: 47

Registration Number: NCT02002195

Locations: 🇮🇹
Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio Ospedaliero San Salvatore, Pesaro, PU, Italy
🇮🇹
Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio San Salvatore,, Pesaro, Italy

STAR Cape+BKM120 MBC With Brain Met

Phase 2

Completed

Conditions: Brain Metastases
Metastatic Breast Cancer
Breast Cancer

Interventions: Drug: BKM120
Drug: capecitabine
Drug: Trastuzumab

First Posted Date: 2013-12-04

Last Posted Date: 2022-02-07

Lead Sponsor: US Oncology Research

Target Recruit Count: 10

Registration Number: NCT02000882

Locations: 🇺🇸
Please contact Zuzanne Bristow for list of sites, Multiple Locations, Texas, United States

Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Metastatic gpNMB Over-expressing Triple Negative Breast Cancer

Interventions: Drug: CDX-011
Drug: Capecitabine

First Posted Date: 2013-11-28

Last Posted Date: 2019-03-08

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 327

Registration Number: NCT01997333

Locations: 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇮🇹
Fondazione Policlinico Universitario A Gemelli, Roma, Lazio, Italy
🇪🇸
Hospital Regional Universitario de Malaga - Hospital General, Malaga, Málaga, Spain

and more 137 locations